Trial record 4 of 15 for:    Open Studies | "Tracheal Diseases"

trūFreeze® Spray Cryotherapy Patient Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by CSA Medical, Inc.
Information provided by (Responsible Party):
CSA Medical, Inc. Identifier:
First received: February 27, 2013
Last updated: July 6, 2015
Last verified: July 2015

To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.

Condition Intervention
Barrett Esophagus
Esophageal Dysplasia
Esophageal Neoplasm
Esophageal Stenosis
Bronchial Neoplasm
Stenosis of Bronchus or Trachea
Device: truFreeze Spray Cryotherapy

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: trūFreeze® Spray Cryotherapy Patient Registry

Resource links provided by NLM:

Further study details as provided by CSA Medical, Inc.:

Primary Outcome Measures:
  • Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    The registry population consists of patients who are being treated using the trūFreeze® spray cryotherapy device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.

Secondary Outcome Measures:
  • Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    All adverse events occurring during the registry period must be recorded. The clinical course of each event should be followed until resolution, stabilization, or until it has been determined that the registry treatment or participation is not the cause. Serious adverse events that are still ongoing at the end of the Spray Cryotherapy Patient Registry registry period must be followed up to determine the final outcome. Any serious adverse event that occurs after the registry period and is considered to be possibly related to the trūFreeze® spray cryotherapy device or registry participation should be recorded and reported immediately.

Estimated Enrollment: 1000
Study Start Date: April 2013
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
truFreeze spray cryotherapy
truFreeze Spray Cryotherapy administered as routine clinical care
Device: truFreeze Spray Cryotherapy
spray cryotherapy

Detailed Description:

This is a prospective, multi-center registry of patients who are currently undergoing spray cryotherapy using the trūFreeze® device. The registry population consists of patients who are being treated using the spray cryotherapy trūFreeze® device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.

Patients eligible to participate in the registry will have disease and treatment specific data collected throughout therapy and long-term follow-up. Subjects will be considered to have completed the registry when data from the 5 year follow-up visit has been collected. The beginning of the follow-up period commences with the first endoscopic treatment session.

Subjects may be withdrawn prior to this for any of the following reasons:

  1. Death, or
  2. Lost to Follow-Up, or
  3. Withdrawal of consent, or
  4. Discontinuation by the investigator. Three attempts at contact using two different methods are required prior to determination that the subject is lost to follow-up. Attempts at contact must be with certified letters OR documented telephone contact.

The registry will utilize electronic case report forms using a web-based platform housed at the University of North Carolina at Chapel Hill. Access to the database will be limited to individuals involved in the research registry and will require a unique user ID and password. All access to the database and web-based application will be encrypted (HTTPS) and electronic systems compliant with applicable privacy and security regulations. To maintain patient confidentiality, all subjects will be assigned a registry identification number, and this will be the only link between subject identity and treatment information. Read-only access will be provided to any personnel who is not an administrator or responsible for data entry.

All data requested on the case report form must be recorded. All missing data must be explained. The system allows sites to directly enter data electronically, however sites are still responsible for ensuring they have source documents that support all data entered electronically that are separate and verifiable. The registry system will maintain an audit trail that captures when electronic entries are changed, what the change was, and who made the change.

The investigators will ensure the capability for inspections of applicable registry-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). The registry will be monitored by the sponsor, and allow auditing by the Institutional Review Board, government regulatory bodies, and University compliance and quality assurance groups of all registry related documents (e.g. source documents, regulatory documents, data collection instruments, registry data, etc.).


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who are being treated using the trūFreeze® spray cryotherapy device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal (GI) setting.


Inclusion Criteria:

  1. GI conditions include:

    • Barrett's Esophagus (BE) with or without dysplasia
    • Squamous dysplasia
    • Esophageal cancer, any stage
  2. Pulmonary conditions include:

    • Any endobronchial cancerous or precancerous disease located within the central airways
    • Any non-malignant endobronchial process of the central airways that results in abnormal mucosa (i.e. granulation tissue, papillomatosis, sarcoidosis, tuberculosis, etc.)
    • Tracheal or bronchial stenosis (malignant or benign)
    • Any pleural disease, malignant or benign All subjects are required to be able to provide written informed consent

Exclusion Criteria:

  1. Gastrointestinal Exclusion Criteria

    • Contraindication to spray cryotherapy.
    • Prior treatment with spray cryotherapy. Previous or concurrent treatment using other mucosal therapies such as endoscopic mucosal resection or radiofrequency ablation is acceptable.
    • Below 18 years of age
  2. Pulmonary Exclusion Criteria

    • Contraindication to spray cryotherapy.
    • Prior treatment with spray cryotherapy. Previous or concurrent treatment using other mucosal therapies is acceptable.
    • Tracheoesophageal fistula.
    • Bronchopleural fistula.
    • Current untreated pneumothorax.
    • Clinically significant hypoxia refractory to supplemental oxygen therapy.
    • Below 18 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01802203

United States, California
Scripps Green Hosptial Recruiting
La Jolla, California, United States, 92037
Contact: Franklin Tsai, MD    858-605-7390   
Contact: Cynthia Galm, RN    858-652-5571   
Principal Investigator: Franklin Tsai, MD         
Sub-Investigator: Walter Coyle, MD         
Sub-Investigator: Shireen Ghorbani, MD         
United States, Colorado
University of Colorado Denver Recruiting
Denver, Colorado, United States, 80045
Contact: Alissa Bi;ts, MPH    303-724-6670   
Principal Investigator: Norio Fukami, MD         
United States, Florida
Borland-Groover Clinic Recruiting
Jacksonville, Florida, United States, 32256
Contact: Marc Lojacono    904-680-0871   
Contact: Laura Walter    904-680-0871   
Principal Investigator: Jose Nieto, DO         
United States, Louisiana
Ochsner Medical Center Recruiting
Kenner, Louisiana, United States, 70065
Contact: Casey Eichler, RN    504-842-8499   
Contact: Maria Waight    504-842-4548   
Principal Investigator: Virendra Joshi, MD         
United States, Maryland
University of Maryland Recruiting
Baltimore, Maryland, United States, 21210
Contact: Bruce Greenwald, MD    410-328-8731   
Contact: Ashutosh Sachdeva, MBBS    410-328-8141   
Principal Investigator: Bruce Greenwald, MD         
Sub-Investigator: Ashutosh Sachdeva, MBBS         
Walter Reed National Military Medical Center Recruiting
Bethesda, Maryland, United States, 20889
Contact: Robert Browning, MD    301-295-4191   
Contact: Maggie Nellissery    301-295-8713   
Principal Investigator: Robert Browning, MD         
Sub-Investigator: Scott Parrish, MD         
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Douglas Pleskow, MD    617-632-8623   
Contact: Johanne Delerme-Joseph   
Principal Investigator: Douglas Pleskow, MD         
Boston University Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Emma Pinjic    617-638-9136   
Contact: Marina Malikova, PhD    617-414-6836   
Principal Investigator: HIran C Fernando, MD         
Sub-Investigator: Virginia Litle, MD         
Massachusetts General Hosptial Recruiting
Boston, Massachusetts, United States, 02114
Contact: Matthew Klebanoff    617-643-4568   
Principal Investigator: Norman Nishioka, MD         
United States, New York
ProHEALTH Care Associates Recruiting
Lake Success, New York, United States, 11042
Contact: Kimberly Gallub, RN    516-622-6145   
Principal Investigator: Matthew McKinley, MD         
NYU Recruiting
New York, New York, United States, 10016
Contact: Audrey Sorensen, RN    212-263-2562   
Principal Investigator: Costas Bizekis, MD         
Sub-Investigator: Michael Zervos, MD         
Sub-Investigator: Seth Gross, MD         
University of Rochester/Strong Memorial Medical Center Recruiting
Rochester, New York, United States, 14642
Contact: Dustina Holt, MPH    585-275-0803   
Principal Investigator: Vivek Kaul, MD         
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Susan Moist, MS    919-843-2508   
Contact: Sarah McGee    919-843-2508   
Principal Investigator: Nicholas J Shaheen, MD, MPH         
United States, Ohio
Ahuja Medical Center-CWR University Hosptials Recruiting
Beachwood, Ohio, United States, 44122
Contact: Lisa Stuart, RN    216-593-1325   
Principal Investigator: John Dumot, DO         
Sub-Investigator: Amitabh Chak, MD         
United States, Pennsylvania
Temple University Health System Recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Marian DeBacker, BSN    215-707-7143   
Principal Investigator: Abbas Abbas, MD         
United States, Rhode Island
Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Jan Clark, RN    401-444-7344   
Principal Investigator: Fadlallah Habr, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Brenda Hoffman, MD    843-876-4265   
Contact: April Wood    843-876-4718   
Principal Investigator: Brenda Hoffman, MD         
Sub-Investigator: Tammy Davidson, ANP         
Sponsors and Collaborators
CSA Medical, Inc.
Principal Investigator: Nicholas Shaheen, MD University of North Carolina, Chapel Hill
Study Director: Ellen Sheets, MD CSA Medical, Inc.
  More Information

Heier SK. Evaluation of candidate therapies for ablation of Barrett's in a canine model. Gastrointestinal endoscopy. 1996;43(4):337
Evantash E, Hill EC, Pernoll ML. Benign disorders of the uterine cervix. Current Obstetric& Gynecologic, Diagnosis & Treatment. 9th ed. Beijing: The McGraw-Hill Companies. 2003:677-692
Holschneider CH. Premalignant and malignant disorders of the uterine cervix. Current Diagnosis and Treatment Obstetrics and Gynecology,. 2007:833-854
Johnston MH. Cryoablation of Dysplasia in Barrett's Esophagus (BE) and Early Stage Esophageal Cancer. Gastrointestinal endoscopy. 2006;63(5):AB223
Johnston MH. Reversal of barrett's esophagus with cryotherapy. The American journal of gastroenterology. 2003;98:S11

Responsible Party: CSA Medical, Inc. Identifier: NCT01802203     History of Changes
Other Study ID Numbers: CSA-003
Study First Received: February 27, 2013
Last Updated: July 6, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by CSA Medical, Inc.:
Barrett esophagus
Esophageal dysplasia
Upper gastrointestinal squamous dysplasia
Esophageal cancer
Endobronchial cancer
Central airway cancer
Central airway precancerous disease
Central airway granulation tissue
Central airway papillomatosis
Central airway sarcoidosis
Central airway tuberculosis
Tracheal stenosis
Bronchial stenosis

Additional relevant MeSH terms:
Barrett Esophagus
Bronchial Neoplasms
Constriction, Pathologic
Esophageal Neoplasms
Esophageal Stenosis
Bronchial Diseases
Digestive System Abnormalities
Digestive System Diseases
Digestive System Neoplasms
Esophageal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Lung Neoplasms
Neoplasms by Site
Pathological Conditions, Anatomical
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on August 31, 2015